BPH - Benign Prostatic Enlargement

BPH - Benign Prostatic Enlargement

UroLift to Preserve Seminal Parameters in Young Male with LUTS from BPH - Beyond the Abstract

In the era of BPH surgery, for the first time, sexual trifecta results are reported as ejaculation preservation, erection preservation, and fertility preservation, following UROLIFT!

5α-reductase inhibitors with or without alpha-blockers and risk of incident upper tract urothelial carcinoma in men with benign prostatic hyperplasia: Analysis of US insurance claims data.

Increasing data suggests that androgen receptor signaling may play an important role in the carcinogenesis of urothelial cancers. While the chemoprotective effect of 5-alpha reductase inhibitors (5-ARi) on bladder cancer risk in men with Benign Prostatic Hyperplasia (BPH) has been explored with conflicting results, the evidence regarding 5-ARi treatment, and the risk of incident Upper Tract Urothelial Carcinoma (UTUC) development is lacking.

Does Concordance Between Preoperatively Measured Prostate Volume and Enucleated Weight Predict Outcomes in Endoscopic Enucleation of the Prostate? Results from the REAP Database - Beyond the Abstract

Continued advancements in anatomical endoscopic enucleation of the prostate (AEEP) for BPH have resulted in better functional outcomes and lower complication rates compared to TURP. Most commonly, preoperative transabdominal ultrasound is used to estimate prostate volume and weight. Residual prostate weight has been found to correlate with postoperative Qmax and symptom scores in TURP.1

LUTS/BPH increases the risk of depressive symptoms among elderly adults: A 5-year longitudinal evidence from CHARLS.

The prevalence of Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) is notably high and potentially elevates the likelihood of depressive symptoms. This study was designed to employ both cross-sectional and longitudinal methodologies to explore the correlation between LUTS/BPH and depressive symptoms among middle-aged and elderly men in China.

Functional outcomes following external beam radiation therapy for patients with prior holmium laser enucleation of the prostate.

Holmium laser enucleation of the prostate (HoLEP) is an increasingly popular size-independent technique of treating male voiding dysfunction due to benign prostatic hypertrophy. Some patients after HoLEP may develop clinically significant prostate cancer and opt for definitive treatment with external beam radiation therapy (EBRT).

A comparison of the efficacy of dutasteride on reducing lower urinary tract symptoms among patients with small versus large benign prostatic hyperplasia.

Only a few reports have currently studied the efficacy of dutasteride in patients with small benign prostatic hyperplasia (BPH). We investigated the efficacy of dutasteride on reducing lower urinary tract symptoms among them.

Establishing and characterizing the molecular profiles, cellular features, and clinical utility of a patient-derived xenograft model using benign prostatic tissues.

Benign Prostatic Hyperplasia (BPH) is a common condition marked by the enlargement of the prostate gland, which often leads to significant urinary symptoms and a decreased quality of life. The development of clinically relevant animal models is crucial for understanding the pathophysiology of BPH and improving treatment options.

Aquablation at 4-years: Real World Data from the Largest Single-Center Study with Associated Outcomes Follow-up - Beyond the Abstract

Our 4-year efficacy and safety data on Aquablation treatment of men with moderate to severe Benign prostatic hyperplasia (BPH) is the largest single-center, single-surgeon experience in the urologic literature. We are happy to report similar results to those previously documented in the WATER and WATER II trials.1,2 In the WATER trial, Aquablation was compared to TURP for treatment of BPH in men with prostate glands 30 to 80 grams confirming similar reductions in IPSS scores between the two groups.

Hypoxia activates the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in a prostatic stromal cell line: A mechanism for the pathogenesis of benign prostatic hyperplasia.

The development of benign prostatic hyperplasia (BPH) is closely related to hypoxia in the prostatic stroma, and the hypoxia-inducible factor-1α/vascular endothelial growth factor (HIF-1α/VEGF) pathway has been shown to significantly activate in response to hypoxia.

Transurethral Resection of the Prostate (TURP) and concomitant inguinal hernioplasty: a single-center experience.

Benign prostatic hyperplasia (BPH) is a prevalent condition in aging males, leading to bladder outlet obstruction (BOO) and associated urinary symptoms. With increasing life expectancy, the incidence of BPH and its co-morbidities, like inguinal hernia, has risen.

A Systematic Review and Single-Arm Meta-Analysis on the Efficacy of High-Intensity, Focused Ultrasound for Benign Prostatic Hyperplasia Treatment: A Forgotten Option?

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of prostate tissue, commonly affecting older men. This condition leads to lower urinary tract symptoms (LUTS), which significantly affect the quality of life.

Clinical Outcomes in Patients with Hypocontractile Bladders Undergoing Holmium Laser Enucleation of the Prostate.

To compare post-operative outcomes in patients who underwent holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia (BPH) and had urodynamic evidence of bladder hypocontractility versus those with normocontractile bladders.

A Multifaceted Assessment of Benign Prostatic Hyperplasia Practice and AUA Guideline Adherence.

Guidelines for benign prostatic hyperplasia (BPH) were initially formulated by the AUA to provide evidence-based reasoning for the management and care of men suffering from lower urinary tract symptoms due to BPH.

Evaluation of the Learning Curve for Thulium Fiber Laser Enucleation of Prostate (ThuFLEP): Retrospective Study of a Single-Surgeon Experience in Real-World Settings - Beyond the Abstract

In our study of the learning curve for Thulium Fiber Laser Enucleation of the Prostate (ThuFLEP), we retrospectively analyzed a single surgeon's experience after 80 initial cases. We found that about 60 cases were needed to achieve proficiency with this technique

Feasibility Assessment of Catheter-Free Water Vapor Thermal Therapy for Treatment of Benign Prostatic Hyperplasia - Beyond the Abstract

Several surgical treatment options are available for benign prostatic hyperplasia (BPH), with the recent emergence of minimally invasive surgical therapies (MIST).1 Water vapor thermal therapy (WVTT; Rezum, Boston Scientific, Marlborough, MA, USA) is desirable given the preservation of erectile and ejaculatory function.2 However, one limitation of this procedure is the need for discharge home with a Foley catheter for an average duration of 3-5 days.3

Comparison of Clinical Therapeutic Efficacy between TUPKP and HoLEP for Patients Aged 70 Years and Older with Benign Prostatic Hyperplasia: Retrospective Study.

The occurrence of prostate hyperplasia has increased remarkedly, especially in elderly patients; However, research on which surgical treatment is effective and safe for benign prostatic hyperplasia (BPH) in elderly people over 70 years old is limited.

Factors associated with concomitant prostate cancer in benign prostatic hyperplasia patients aged 60 years and above.

Prostate hyperplasia and cancer are more prevalent in middle-aged and elderly men. Previous studies have linked both disorders to androgen receptors. Herein, efforts were made to identify factors associated with prostate cancer in patients ≥60 years, aiming to enhance their health management.

Prostate-specific antigen, androgen, progesterone and oestrogen receptors in Benign prostatic hyperplasia: human tissues and animal model study.

Direct evidence for the relationship between a large prostate (≥80 ml) and androgen receptor/PSA signal remains lacking in benign prostatic hyperplasia (BPH). Our aim is to identify whether the cause of a large prostate is related to progesterone receptor (PGR) androgen receptor (AR), oestrogen receptor α, β (ERα,β) and prostate-specific antigen (PSA).

Prostate Artery Embolization with 4D-CT.

Prostate artery embolization (PAE) is a technically challenging angiographic therapy that has been shown to have excellent clinical outcomes for men with benign prostatic hyperplasia and lower urinary tract symptoms.

Non-Surgical Bleeding and Transurethral Resection of the Prostate (TURP) Syndrome after TURP Surgery: A Case Report and Literature Review.

Patients undergoing transurethral resection of the prostate (TURP) surgery can develop TURP syndrome and post-TURP bleeding. Post-TURP bleeding can be surgical, from arteries or venous sinuses, or non-surgical, due to coagulopathy preventing clot formation.

Page 1 of 144